晶碩 6491
Listed · Biotechnology and medical care- Open
- 393.00
- High
- 395.50
- Low
- 386.50
- Prev close
- —
- Volume (lots)
- 253
- Turnover
- 0.99 億
- P/E
- 16.4
- Cash yield
- 2.55%
Financial trends
Loading…
Consolidated statements; NT$100M (per-share items in NT$). Updated after each quarterly filing (MOPS). Some line items do not apply to financial companies.
Unit: 100 million TWD (EPS in TWD)Source: public data from MOPS, TWSE, TPEx and TDCC
Loading…
Figures are shown as announced, with no scoring or rating.
No data.
No data.
Revenue in NT$100M; 12 months per page.
| Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.5 | 21.1 | 18.9 | 19.3 | 18.9 | 16.3 | 15.9 | 17.9 |
| Cost of revenue | 10.8 | 9.9 | 8.8 | 9.1 | 9.3 | 8.0 | 7.2 | 8.1 |
| Gross profit | 11.7 | 11.2 | 10.1 | 10.2 | 9.6 | 8.3 | 8.8 | 9.8 |
| Operating expenses | 5.4 | 5.4 | 4.6 | 5.0 | 4.8 | 4.5 | 4.5 | 4.9 |
| Operating income | 6.3 | 5.8 | 5.4 | 5.2 | 4.8 | 3.8 | 4.3 | 4.9 |
| Non-operating items | 0.2 | 0.7 | 0.2 | 0.3 | 0.3 | 0.1 | 1.5 | -0.0 |
| Pre-tax income | 6.4 | 6.5 | 5.7 | 5.5 | 5.1 | 3.8 | 5.8 | 4.8 |
| Income tax | 1.0 | 1.0 | 0.9 | 1.1 | 1.0 | 0.6 | 0.9 | 0.7 |
| Continuing operations | 5.4 | 5.5 | 4.8 | 4.3 | 4.0 | 3.2 | 4.9 | 4.1 |
| Net income | 5.4 | 5.5 | 4.8 | 4.3 | 4.0 | 3.2 | 4.9 | 4.1 |
| Net income to parent | 5.4 | 5.4 | 4.7 | 4.3 | 4.0 | 3.1 | 4.9 | 4.1 |
| Net income to NCI | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 |
| Other comprehensive income | 0.2 | -0.1 | 0.3 | -0.2 | 0.2 | -1.2 | 0.2 | -0.1 |
| Total comprehensive income | 5.6 | 5.4 | 5.0 | 4.2 | 4.2 | 2.0 | 5.1 | 4.1 |
| EPS (TWD) | 6.96 | 7.07 | 6.06 | 5.49 | 5.09 | 4.02 | 6.27 | 5.24 |
Amounts in NT$100M (per-share items in NT$).
| Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Current assets | 65.3 | 69.5 | 69.8 | 65.4 | 65.0 | 66.1 | 58.4 | 59.2 |
| Non-current assets | 103.3 | 100.1 | 96.6 | 96.4 | 94.4 | 91.8 | 90.6 | 86.3 |
| Total assets | 168.6 | 169.6 | 166.4 | 161.7 | 159.4 | 157.9 | 149.0 | 145.5 |
| Current liabilities | 37.3 | 47.1 | 47.1 | 38.2 | 40.2 | 42.5 | 34.8 | 27.9 |
| Non-current liabilities | 5.0 | 5.9 | 6.2 | 6.2 | 6.0 | 6.4 | 7.1 | 7.0 |
| Total liabilities | 42.3 | 52.9 | 53.3 | 44.4 | 46.2 | 48.9 | 41.9 | 34.9 |
| Share capital | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 |
| Capital surplus | 42.8 | 42.8 | 42.7 | 42.7 | 42.7 | 42.7 | 42.7 | 42.7 |
| Retained earnings | 74.4 | 69.4 | 64.0 | 67.1 | 62.8 | 58.8 | 55.7 | 59.4 |
| Other equity | -0.9 | -1.1 | -1.0 | -1.3 | -1.1 | -1.2 | -0.0 | -0.2 |
| Treasury stock | 0.0 | -3.4 | -1.5 | — | — | — | — | — |
| Equity to parent | 124.1 | 115.6 | 112.0 | 116.3 | 112.2 | 108.1 | 106.2 | 109.7 |
| Non-controlling interests | 2.2 | 1.1 | 1.1 | 1.0 | 1.0 | 0.9 | 1.0 | 0.9 |
| Total equity | 126.3 | 116.7 | 113.1 | 117.4 | 113.2 | 109.0 | 107.1 | 110.6 |
| Book value per share (TWD) | 159.15 | 150.52 | 144.58 | 149.12 | 143.87 | 138.60 | 136.10 | 140.59 |
Amounts in NT$100M (per-share items in NT$).
| Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.3 | 8.3 | 0.8 | 6.2 | 7.4 | 2.9 | 10.0 | 11.4 |
| Investing cash flow | 8.6 | -6.6 | -7.1 | -2.5 | 0.7 | -5.3 | -14.2 | -4.5 |
| Financing cash flow | -2.4 | -6.2 | 1.1 | -3.2 | -6.8 | 4.1 | -2.0 | -2.9 |
| FX effect | 0.1 | -0.0 | 0.1 | 0.1 | 0.1 | -0.6 | 0.2 | -0.1 |
| Net change in cash | 9.6 | -4.6 | -5.0 | 0.5 | 1.5 | 1.1 | -6.0 | 3.9 |
| Cash, beginning | 17.1 | 17.1 | 17.1 | 20.0 | 20.0 | 20.0 | 20.0 | 15.0 |
| Cash, ending | 17.0 | 7.4 | 12.0 | 17.1 | 16.5 | 15.1 | 14.0 | 20.0 |
Amounts in NT$100M (per-share items in NT$).
No data.
No data.
Source: MOPS. For reference only; not investment advice.